HICA,
does it really help with Increased muscle mass, reduced muscle loss, and enhanced post-exercise recovery?
research showsC. Human efficacy literature exists for HICA and is limited and conflicting. A patent-linked pilot in 15 male soccer players reported some positive findings for lean mass and subjective soreness at one timepoint. By contrast, a 40-participant multi-arm trial included only 10 HICA and 10 placebo participants in the direct comparison and found no benefit for muscle thickness, strength, or power. That null comparison is too small to meet the large human null-evidence criterion for D, so limited, conflicting, manufacturer-linked positive evidence gives C with 42 points.
ads claimMarketing uses the leucine-metabolite mechanism and the 15-person pilot to promise blocked muscle breakdown, reliable lean-muscle gain, and pain-free rapid recovery. It commonly omits that the later multi-arm trial found no added growth or performance in the direct comparison of 10 HICA and 10 placebo participants.
Useful facts when choosing a product
- HICA is 2-hydroxyisocaproic acid, a leucine metabolite distinct from HMB, and evidence for the two compounds cannot be substituted.
- Human trials mainly used 1.5 g daily for four to eight weeks, so effects and safety at other doses or during long-term use are unknown.
- When HICA appears in a multi-ingredient pre-workout or recovery product with creatine, caffeine, or amino acids, any observed effect cannot be attributed to HICA alone.
- Short trials did not reveal a prominent serious-adverse-event signal, but samples were too small to establish long-term hepatic, renal, or metabolic safety.
What the research actually shows
Mero 2010 randomized 15 male soccer players to HICA 1.5 g daily or maltodextrin for four weeks. Lower-extremity lean mass rose by about 400 g with HICA and fell by 150 g with placebo, and whole-body soreness was lower in week four, but strength and running speed did not differ. Teixeira 2019 randomized 40 young men to HICA 10, HMB free acid 11, HMB calcium 9, or placebo 10 during resistance training three times weekly for eight weeks. All groups improved with training, but HICA produced no added effect on muscle thickness, performance, hormones, or creatine kinase.
Why this is classified as C (42)
C. A patent-linked 15-person pilot reported some positive lean-mass and subjective-soreness findings, while a 40-participant multi-arm trial with 10 HICA and 10 placebo participants in the direct comparison found null muscle-thickness, strength, and power results. The direct null comparison is too small for the large human null-evidence criterion for D. Limited, conflicting, manufacturer-linked positive evidence gives C with 42 points. Short-term safety evidence remains separately limited.
Counterpoint. Adequate energy and protein intake, progressive resistance training, sleep, and training-load management have far stronger evidence for muscle gain and recovery. HICA does not replace them.
Rejudgment record. Reassessment (cross-check reflected) — Applied C because a patent-linked 15-person pilot had some positive lean-mass and subjective-soreness findings while a 40-participant multi-arm trial had only 10 HICA and 10 placebo participants in the direct comparison and found null muscle-thickness, strength, and power results; that small null comparison does not meet the large human null-evidence criterion for D, fitting limited, conflicting, manufacturer-linked positive evidence
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Increased muscle mass and reduced muscle loss | C | Some positive findings in a 15-person pilot conflict with null objective muscle outcomes in a direct comparison of 10 HICA and 10 placebo participants. |
| Post-exercise recovery and delayed-onset muscle soreness | C | A positive subjective soreness finding at one timepoint was not reproduced in objective recovery or performance outcomes, leaving limited conflicting evidence. |
| Inability to attribute multi-ingredient pre-workout effects to HICA | ? | Results obtained with other active ingredients cannot isolate an HICA-only effect. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Mero AA et al. 2010 | Four-week double-blind randomized placebo-controlled pilot | 7 | Two authors were HICA patent inventors and partners in Oy Elmomed | DXA lean mass, subjective delayed-onset muscle soreness, strength, and running speed | Lower-extremity lean mass and week-four subjective soreness favored HICA, but strength and running speed did not differ. | Very small conflicted positive evidence |
| Teixeira FJ et al. 2019 | Eight-week double-blind multi-arm randomized placebo-controlled trial | 10 | Authors reported no conflicts of interest | Muscle thickness, DXA body composition, strength, power, hormones, and creatine kinase | The direct comparison of 10 HICA and 10 placebo participants found no significant added benefit for muscle thickness, strength, power, or any other outcome. | Small direct follow-up failure to replicate |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-07-19).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-19 · Corrections: none
Cite this verdict
[Chamgap] HICA x muscle gain, anticatabolic effects, and exercise recovery — Evidence Grade C·42. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/sports/hica-muscle-gain-anticatabolic-exercise-recovery/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.